Published in J Clin Oncol on September 01, 2002
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res (2009) 1.71
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol (2011) 1.24
Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J Interferon Cytokine Res (2013) 1.07
Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs (2008) 1.05
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol (2010) 0.91
Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol (2011) 0.90
Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev (2012) 0.86
Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. Curr Oncol (2008) 0.84
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res (2011) 0.82
Modulation of inflammasome-mediated pulmonary immune activation by type I IFNs protects bone marrow homeostasis during systemic responses to Pneumocystis lung infection. J Immunol (2013) 0.81
Chronic exposure to IFNα drives medullar lymphopoiesis towards T-cell differentiation in mice. Haematologica (2015) 0.78
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery. Clinicoecon Outcomes Res (2012) 0.78
Adjuvant treatment of melanoma. ISRN Dermatol (2013) 0.78
Interferon-α induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor. J Interferon Cytokine Res (2014) 0.78
A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type I IFN Response. J Innate Immun (2015) 0.77
IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy (2016) 0.76
The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. J Immunol Res (2016) 0.75
Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma. Clinicoecon Outcomes Res (2015) 0.75
Combination immunotherapy for high-risk resected and metastatic melanoma patients. Ochsner J (2014) 0.75
Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol (2014) 0.75
Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection. Br J Clin Pharmacol (2016) 0.75
Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective. Support Care Cancer (2012) 0.75
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. Front Immunol (2017) 0.75
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Preconception care: a systematic review. Matern Child Health J (2002) 2.83
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 1.84
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol (2006) 1.83
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
In-center nocturnal hemodialysis: another option in the management of chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.39
Red blood cell survival in chronic renal failure. Am J Kidney Dis (2004) 1.34
Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) (2002) 1.32
Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg (2010) 1.20
Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer (2005) 1.08
Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery (2007) 1.04
I could lose everything: understanding the cost of a brain tumor. J Neurooncol (2007) 1.04
A preliminary study of PDA-based dietary self-monitoring in hemodialysis patients. J Ren Nutr (2005) 1.04
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res (2011) 1.03
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol (2011) 0.94
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 0.92
The salvage of aneurysmal fistulae utilizing a modified buttonhole cannulation technique and multiple cannulators. Hemodial Int (2006) 0.91
The antihypertensive and vasodilator effects of aqueous extract from Berberis vulgaris fruit on hypertensive rats. Phytother Res (2005) 0.90
Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol (2011) 0.90
Cerebrospinal fluid 20-HETE is associated with delayed cerebral ischemia and poor outcomes after aneurysmal subarachnoid hemorrhage. Stroke (2011) 0.87
Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy. Psychooncology (2010) 0.85
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res (2007) 0.84
Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg (2007) 0.83
Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev (2012) 0.81
Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clin Trials (2007) 0.80
Brachytherapy in the treatment of Stage IV carcinoma of the base of tongue. Brachytherapy (2004) 0.78
Exploring spirituality in family caregivers of patients with primary malignant brain tumors across the disease trajectory. Oncol Nurs Forum (2013) 0.78
Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78
Self-reported exercise during breast cancer treatment: results of a national survey. Cancer Nurs (2010) 0.77
Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev (2006) 0.76
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc Pharmacol (2013) 0.76
Exploring the impact of a decision support intervention on vascular access decisions in chronic hemodialysis patients: study protocol. BMC Nephrol (2011) 0.76
Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b". Oncologist (2006) 0.75
Erythropoietin in kidney disease and type 2 diabetes. N Engl J Med (2011) 0.75
Gamma Knife Radiosurgery for Malignant Melanoma Brain Metastases 907. Neurosurgery (2006) 0.75
Development of competencies for the use of bedside ultrasound for assessment and cannulation of hemodialysis vascular access. CANNT J (2016) 0.75
Are you SURE about your vascular access? Exploring factors influencing vascular access decisions with chronic hemodialysis patients and their nurses. CANNT J (1) 0.75
Correlation between fractional reabsorption of sodium and erythropoietin dose in peritoneal dialysis patients. Perit Dial Int (2006) 0.75
Making home-made phantom models for hemodialysis ultrasound vascular access assessment and real-time guided cannulation training. CANNT J (2016) 0.75